A 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED STUDY OF GINKO BILOBA AUGMENTATION

银杏叶增强作用的 12 周双盲安慰剂对照研究

• 批准号: 7376057
• 负责人: MICHAEL SMITH
• 金额: $ 1.93万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376057
• 关键词: 12; WEEK; DOUBLE; BLIND; PLACEBO

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To examine whether standardized estracts of Ginko biloba (Gb) might be a useful added agent in treating symptoms of schizophrenia, particularly negative symptoms and/or improve their brain function and memory. The study will use a double-blind, randomized, placebo-controlled design, and will include 100 subjects with treatment resistant schizophrenia. Subjects will be randomized to receive either a standard dose of Gb or placebo for 12 weeks in addition to continuing their treatment with anti psychotic medications that have been judged as optimal prior to entering the study. Standard assessment instruments will be used for measuring changes in symptoms (both positive and negative), neurocognitive performance and functioning status. Assessments will be done at baseline, and at the end of weeks 2,4,6 and 12.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。检验银杏叶标准化提取物（Gb）是否可能是治疗精神分裂症症状，特别是阴性症状和/或改善其脑功能和记忆的有用添加剂。该研究将采用双盲、随机、安慰剂对照设计，并将包括100名患有治疗难治性精神分裂症的受试者。受试者将随机接受标准剂量的Gb或安慰剂12周，并继续服用抗精神病药物，这些药物在进入研究之前被认为是最佳的。标准评估工具将用于测量症状（阳性和阴性）、神经认知表现和功能状态的变化。评估将在基线和第2、4、6和12周结束时进行。